Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Moodys
Express Scripts
Baxter
Medtronic
McKinsey
Merck

Last Updated: December 15, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Onartuzumab

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the development status for investigational drug Onartuzumab?

Onartuzumab is an investigational drug.

There have been 15 clinical trials for Onartuzumab. The most recent clinical trial was a Phase 3 trial, which was initiated on December 1st 2013.

The most common disease conditions in clinical trials are Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, and Stomach Neoplasms. The leading clinical trial sponsors are Hoffmann-La Roche, Genentech, Inc., and M.D. Anderson Cancer Center.

There are fourteen US patents protecting this investigational drug and four hundred and fifty-three international patents.

Recent Clinical Trials for Onartuzumab
TitleSponsorPhase
An Extension Study of Onartuzumab in Patients With Solid Tumors on Study Treatment Previously Enrolled in a Company Sponsored StudyHoffmann-La RochePhase 3
Biomarker-Integrated Approach of Targeted Therapy for Lung Cancer Elimination Plus External Beam Radiation Therapy (BATTLE-XRT)Genentech, Inc.Phase 1/Phase 2
Biomarker-Integrated Approach of Targeted Therapy for Lung Cancer Elimination Plus External Beam Radiation Therapy (BATTLE-XRT)M.D. Anderson Cancer CenterPhase 1/Phase 2

See all Onartuzumab clinical trials

Clinical Trial Summary for Onartuzumab

Top disease conditions for Onartuzumab
Top clinical trial sponsors for Onartuzumab

See all Onartuzumab clinical trials

US Patents for Onartuzumab

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Onartuzumab   Start Trial Multispecific constructs AbbVie Stemcentrx LLC (North Chicago, IL)   Start Trial
Onartuzumab   Start Trial Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein CureVac AG (Tubingen, DE)   Start Trial
Onartuzumab   Start Trial Cancer treatment with c-met antagonists and correlation of the latter with HGF expression Genentech, Inc. (South San Francisco, CA)   Start Trial
Onartuzumab   Start Trial Methods of treating glioblastoma multiforme using ibudilast MediciNova, Inc. (La Jolla, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Onartuzumab

Drugname Country Document Number Estimated Expiration Related US Patent
Onartuzumab Canada 2900764 2033-02-08   Start Trial
Onartuzumab European Patent Office 2954056 2033-02-08   Start Trial
Onartuzumab Hong Kong 1218930 2033-02-08   Start Trial
Onartuzumab Japan 2016509014 2033-02-08   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Merck
Dow
Express Scripts
Colorcon
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.